Many bone fractures show compromised regeneration-healing slowly (delayed union) or failing to heal (non-union). These injuries can be complicated by pain and loss of function, often requiring revision surgery, and are a significant cost to society. A robust vascular response is required for proper bone regeneration, thus a lack of vascularization is a primary risk factor for compromised bone healing. Therefore, methodologies that enhance vascularization will promote greater healing of compromised fractures. Thrombospondin 1 (TSP1) and its closest family member thrombospondin 2 (TSP2) are extracellular matrix proteins and potent endogenous inhibitors of angiogenesis that are over-expressed in non-healing wounds. TSP1 and TSP2 are highly expressed during the fibrovascular phase of compromised fracture healing and an absence of TSP2 results in enhanced vascularization and bone formation during ischemic fracture healing. A dominant mechanism for the influence of TSPs on revascularization in tissues is the interaction of these ligands with the CD47 receptor, a pleiotropic receptor that strongly influences ischemia-reperfusion. However, the significance of TSP-CD47 interactions in enhancing ischemic fracture healing has not been studied. We hypothesize that TSPs are endogenous inhibitors of ischemic fracture healing by binding to CD47. Blocking TSP-CD47 binding will promote fracture vascularization and enhance bone regeneration in compromised fracture healing. To address this hypothesis we propose three specific aims. First we will examine the contribution of TSP1 and TSP2 to ischemic fracture healing by studying TSP1-null, TSP2-null, and double-knockout mice. As well, we will add back TSP2 using adenovirus.
In Aim 2, we will ask whether CD47 regulates fracture vascularization and bone regeneration in compromised fracture healing by binding to TSP. We will examine ischemic fracture healing in CD47-null mice, and then evaluate whether a TSP1-based CD47 activating peptide inhibits ischemic fracture revascularization. Finally, we will ask whether disruption of TSP-CD47 ligand-receptor interaction following fracture healing using CD47 blocking agents, delivered either locally or systemically, can enhances fracture vascularization and bone regeneration in compromised healing. Successful completion of these studies could have significant near-term clinical implications for the patient with a compromised fracture.

Public Health Relevance

Compromised bone fracture healing resulting in non-union and delayed union is a highly-significant clinical problem. A primary factor resulting in compromised fracture healing is lack of proper blood flow, also known as ischemia. We propose that if we can increase blood flow under ischemic conditions, then we can improve fracture healing outcome. Our work will demonstrate the key role of thrombospondin signaling with CD47 in regulating ischemic fracture healing and will disrupt this ligand-receptor interaction to increase healing in an ischemic mouse model.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR066028-06
Application #
9921196
Study Section
Skeletal Biology Structure and Regeneration Study Section (SBSR)
Program Officer
Chen, Faye H
Project Start
2015-09-15
Project End
2021-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Orthopedics
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Zondervan, Robert L; Vorce, Mitch; Servadio, Nick et al. (2018) Fracture Apparatus Design and Protocol Optimization for Closed-stabilized Fractures in Rodents. J Vis Exp :
Knight, M Noelle; Karuppaiah, Kannan; Lowe, Michele et al. (2018) R-spondin-2 is a Wnt agonist that regulates osteoblast activity and bone mass. Bone Res 6:24